| 引用本文: | 叶超,王朝晖,胡英,宋露萍,周维,廖玲珑,王春江.双碳青霉烯方案治疗耐碳青霉烯类肠杆科细菌研究进展[J].中国现代应用药学,2020,37(20):2555-2560. |
| YE Chao,WANG Zhaohui,HU Ying,SONG Luping,ZHOU Wei,LIAO Linglong,WANG Chunjiang.Advances in the Treatment of Carbapenem-resistant Enterobacteria by the Double Carbapenem Regimen[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(20):2555-2560. |
|
| 本文已被：浏览 1766次 下载 1102次 |
码上扫一扫！ |
|
|
| 双碳青霉烯方案治疗耐碳青霉烯类肠杆科细菌研究进展 |
|
叶超1, 王朝晖1, 胡英1, 宋露萍1, 周维1, 廖玲珑2, 王春江3
|
|
1.湖南中医药大学附属宁乡市人民医院药学部, 长沙 410600;2.广州市增城区人民医院消化内科, 广州 511300;3.中南大学湘雅三医院药学部, 长沙 410013
|
|
| 摘要: |
| 近年来，对碳青霉烯类抗菌药物耐药的肠杆科细菌日益增多，临床治疗药物品种有限，死亡率较高。体外实验表明，碳青霉烯酶对厄他培南的亲和力显著高于碳青霉烯类其他品种，从而可消耗碳青霉烯酶，防止与之联用的碳青霉烯其他品种分解。因此，临床有厄他培南联合碳青霉烯类其他品种治疗耐碳青霉烯类肠杆科细菌。本文综述双碳青霉烯联合使用方案的机制、临床疗效及影响因素等，为临床治疗耐碳青霉烯类肠杆科细菌提供借鉴和指导。 |
| 关键词: 双碳青霉烯 耐碳青霉烯肠杆科细菌 作用机制 临床疗效 研究进展 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.20.022 |
| 分类号:R969 |
| 基金项目: |
|
| Advances in the Treatment of Carbapenem-resistant Enterobacteria by the Double Carbapenem Regimen |
|
YE Chao1, WANG Zhaohui1, HU Ying1, SONG Luping1, ZHOU Wei1, LIAO Linglong2, WANG Chunjiang3
|
|
1.Department of Pharmacy, Ningxiang People's Hospital Affiliated to Hunan University of Chinese Medicine, Changsha 410600, China;2.Department of Gastroenterology, Zengcheng District People's Hospital of Guangzhou, Guangzhou 511300, China;3.Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha 410013, China
|
| Abstract: |
| In recent years, carbapenem-resistant Enterobacteria have been increasing, and the variety of clinical treatment drugs is limited, and the mortality rate is high. In vitro experiments have shown that carbapenemase has a significantly higher affinity for ertapenem than other carbapenem varieties, so it can consume carbapenemase and prevent the decomposition of other carbapenem varieties. Therefore, ertapenem is combined with other carbapenems to treat carbapenem-resistant Enterobacteria. This article reviews the mechanism, clinical efficacy and influencing factors of the double carbapene regimen, and provides reference and guidance for the clinical treatment of carbapenem-resistant Enterobacteria. |
| Key words: double carbapenem carbapenem-resistant Enterobacteria mechanism of action clinical efficacy research progress |
